基质金属蛋白酶-1、-2与女性年龄、骨转换生化指标及骨密度的关系

目的 探讨血清基质金属蛋白酶（MMP）-1、MMP-2与女性年龄、骨密度（BMD）及骨转换生化指标之间的关系。方法用ELISA测定591例20-80岁女性志愿者血清MMP-1、MMP-2、血清骨碱性磷酸酶（BAP）、血清骨钙素（OC）和血清Ⅰ型胶原氨基末端肽（NTX）,用DEXA测定腰椎1-4正位总体、股骨颈、Ward三角区、总髋部的BMD。结果（1）MMP-1、MMP-2与年龄呈正相关。（2）绝经后妇女MMP-2水平高于绝经前妇女（P〈0．001）。（3）MMP-2与BMD呈负相关（P〈0．05）,但多元线性回归分析表明MMP-2不是BMD的预测因子。（4）MMP-2与血清BAP、OC、NTX正相关（P〈0．01）。（5）绝经后骨质疏松症患者血清MMP-2水平高于年龄匹配的正常对照组、骨量减少组（P〈0．01）。结论血清MMP-2与骨转换生化指标相关联。血清MMP-2水平升高可能为高骨转换过程（如绝经后骨质疏松症）中的一种伴随表现。     

女性骨转换指标与年龄和腰椎骨密度的关系

目的观察20～80岁健康女性血清骨特异性碱性磷酸酶（sBAP）、血清和尿液中Ⅰ型胶原羧基末端肽（sCTX和uCTX）随年龄变化的规律及其与腰椎正位骨密度（BMD）之间的关系。方法用ELISA法测定sBAP、sCTX和uCTX，以自动分析仪测定血清总碱性磷酸酶（sTAP）和尿肌酐；同时用双能X线骨密度仪测定腰椎正位的BMD。结果（1）年龄与sBAP、sCTX、uCTX和sTAP之间均存在明显的相关性，决定系数（R^2）分别是0.371、0.130、0.121和0.333。（2）在校正年龄、体重及身高的影响之后腰椎正位的BMD与sBAP、sCTX、uCTX和sTAP明显负相关，其与骨转换指标的相关系数（r）分别为-0．37、-0．29、-0．26和-0．30（均P〈0.01）。（3）按腰椎正位的峰值骨量确定正常骨量、低骨量及骨质疏松的人群，发现sBAP、sCTX、uCTX和sTAP在3组之间差异存在统计学意义。结论sBAP、sCTX、uCTX随年龄而变化并与腰椎正位BMD间存在负相关。血清sBAP、sCTX和uCTX在低骨量和骨质疏松的人群中明显升高，提示其是健康女性确定骨转换率的敏感指标。     

正常女性与年龄相关的骨转换生化指标和骨密度的关系

目的　探讨女性人群骨转换生化指标 :血清骨特异性碱性磷酸酶 (sBAP)、血清骨钙素(sOC)和尿Ⅰ型胶原氨基末端肽 (uNTX)随年龄变化及其与骨密度 (BMD)之间的关系。方法　用ELISA测定sBAP、sOC和uNTX ,用DXA仪测定腰椎 1～ 4前后位 (AP)、股骨颈 (FN)的BMD。结果( 1)sBAP、sOC和uNTX与年龄呈正相关 ,3个骨生化指标随年龄的变化均以三次回归模型的拟合程度最好 ,拟合曲线的决定系数 (R2 )为 0 181～ 0 381(P <0 0 0 1)。 ( 2 )按每 10岁年龄段分组发现 :这3个生化指标在 30～ 39岁年龄段最低 ,随后随年龄的增长而升高 ;5 0～ 5 9岁段达最高值。 ( 3)按是否绝经分组结果表明 :绝经后妇女sBAP、sOC和uNTX水平均较绝经前妇女高 (P <0 0 0 1) ,而绝经后妇女的AP、FN部位的BMD都低于绝经前妇女 (P <0 0 0 1)。( 4 )sBAP、sOC与uNTX呈正相关 (P<0 0 0 1) ,sBAP、sOC和uNTX与AP、FN部位的BMD呈负相关 (P <0 0 0 1)。结论　sBAP、sOC和uNTX是反映女性随年龄及绝经变化的骨转换的敏感和较特异的指标 ,能较好地预测BMD ,妇女BMD降低与骨的代谢转换率升高有关。     

中老年妇女骨转换生化指标和骨密度的变化

目的 探讨中老年妇女骨转换生化指标与骨密度随绝经的变化.方法 408名符合条件40 ～80岁的女性志愿者,同一时间段留取血清和晨尿,统一用酶免方法 测定血清骨碱性磷酸酶(BAP)、骨钙素和尿I型胶原氨基末端肽(uNTX);用舣能X线骨密度仪测定前后位腰椎1-4(L1-4)、左侧股骨颈的骨密度.结果 (1)BAP、骨钙素和uNTX与年龄、孕次、生育次数和绝经年限呈正相关(均P相似文献   

基质金属蛋白酶及其组织抑制因子与糖尿病足

创面修复是一个复杂而有序的生物学过程,许多重要过程均受细胞因子和蛋白酶的调节。研究表明糖尿病患者足部伤口中基质金属蛋白酶(MMPs)表达增加,其抑制因子基质金属蛋白酶组织抑制因子(TIMPs)表达减少,导致伤口难以愈合。MMPs与TIMPs的比例可能比它们的绝对浓度更重要,是预测伤口愈合的重要指标,与伤口愈合时间呈负相关。局部应用强力霉素、一些含蛋白酶抑制剂的敷料以及促有丝分裂的牛血清提取物等均可通过抑制MMPs促进创面愈合。     

脑膜瘤与基质金属蛋白酶及其组织抑制因子的关系

脑膜瘤是常见的颅内肿瘤,虽然绝大多数脑膜瘤组织学表现良性,却常可见其侵犯硬膜、颅骨和脑组织.随着对脑膜瘤生物学行为的研究深入,基质金属蛋白酶(MMPs)和其组织抑制因子(TIMPs)在脑膜瘤中所起的作用也逐渐引起了人们的注意.本文就MMPs和TIMPs与脑膜瘤关系的研究现状作一综述.     

基质金属蛋白酶及其抑制因子与肝纤维化

基质金属蛋白酶是肝内细胞外基质降解酶的重要酶类。肝内MMP家族包括MMP-1、MMP-2、MMP-3及其抑制因子TIMP-1、TIMP-2、TIMP-3。MMP主要由肝脏间质细胞合成和分泌,TIMP可由肝脏实质及间质细胞合成和分泌。肝纤维化早期时,肝组织间质胶原酶活性较高,纤维化晚期活性下降;而肝纤维化时肝组织中TIMP-1表达增强,慢性肝炎患者血清TIMP-1水平显著增高,并与肝纤维化程度呈显著正相关,提示MMP及TIMP家族对于肝纤维的发生、发展及预后都有重要意义。     

血清基质金属蛋白酶及其组织抑制因子与肝纤维化

在正常肝脏纤维组织中存在着细胞外基质(ECM)的合成与降解的动态平衡。肝纤维化时纤维结缔组织的形成，是由于各种不同致病因子导致ECM合成与降解的失衡所致。基质金属蛋白酶(MMPs)是ECM降解的主要酶系，而其组织抑制因子(TIMPs)通过抑制MMPs，阻止ECM的降解，从而形成或促进肝纤维化。     

脑梗死患者基质金属蛋白酶1，9及其组织抑制因子1与血脂关系的研究

目的 探讨脑梗死患者基质金属蛋白酶1(MMP1)、基质金属蛋白酶9(MMP9)及其组织抑制因子1(TIMP1)与血脂、脑梗死面积的相互关系.方法 选择脑梗死患者40例,分别于发病后第1天、第3天、第7天采集肘静脉血,应用酶联免疫吸附法检测血清MMP1、MMP9及其TIMP1的浓度变化,并检测血脂的变化,通过头颅CT评估脑梗死的面积.结果 脑梗死患者MMP1、MMP9、TIMP1数值在检测不同的天数有不同改变,脑梗死面积增大,则MMP1、MMP9、TIMP1数值变大(P<0.05);血脂指标的改变在脑梗死入院后第7天内无明显变化.结论 脑梗死患者MMP1、MMP9、TIMP1在不同的时间窗存在一定规律的改变,三项血浆浓度与脑梗死面积表现为正相关系,但与患者的血脂无显著性关联.     

基质金属蛋白酶2、基质金属蛋白酶9与急性肺损伤关系的研究进展

急性肺损伤是由多种肺内外因素如严重创伤、感染、休克、脓毒症和大量输血等原因引起的弥漫性肺实质损伤.各种原因引起一系列炎症细胞在肺内聚集和活化,释放细胞因子、生长因子及其他炎症介质,引起基质金属蛋白酶(MMP)的合成和活化.MMP-2、MMP-9通过破坏基底膜、促进炎症过程中有关细胞的迁移以及细胞外基质重建,在急性肺损伤...     

Quantitative ultrasound is better correlated with bone mineral density and biochemical bone markers in elderly women

The association between quantitative ultrasound (QUS) and bone turnover in postmenopausal women of different ages is an area of continuous investigation. The aim of this study was to investigate the relationship of ultrasound parameters [broadband ultrasound attenuation (BUA) and speed of sound (SOS)] to bone mineral density (BMD) and biochemical markers of bone turnover in three age groups of postmenopausal women. One hundred and twenty-three postmenopausal Caucasian women were divided into three groups according to their age: group A, range 44–54 years, mean age (±SD) 48.3 ± 2.3; group B, range 55–65 years, mean age 59.4 ± 2.1; and group C, range 66–77 years, mean age 68.2 ± 3.1. Ultrasound parameters were measured by the DTU-one imaging ultrasonometer in the calcaneus. BMD was assessed by dual-energy X-ray absorptiometry (DEXA) at the lumbar spine, femoral neck, and trochanter. Bone turnover was assessed by serum bone-specific alkaline phosphatase (BAP), urinary excretion of free deoxypyridinoline, N-telopeptides (NTX), and C-telopeptide breakdown products of type I collagen (CTX). QUS and BMD were significantly correlated in all sites, except hip BMD in group A. The most significant correlation was observed between BUA and femoral neck BMD in group C (r = 0.626, p < 0.01). BUA correlated significantly with BAP, NTX, and CTX (r = −0.434, −0.511, −0.478, respectively; p < 0.01), and SOS with BAP and NTX (r = −0.351 and −0.356, respectively; p < 0.05) only in group C. In groups A and B, ultrasound parameters did not correlate significantly to biochemical markers. Ultrasound parameters were better correlated to hip BMD and to biochemical markers of bone turnover in elderly postmenopausal women. These ultrasound measurements could be used as a screening test for bone status, either in nonambulatory third aged women or in those living in rural areas where attending medical centers with DEXA equipment and biochemical laboratories is difficult.     

The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis

Abstract

The aim of this study was to investigate determinants of reduced bone mineral density (BMD) in postmenopausal women with active rheumatoid arthritis (RA) and to evaluate whether there are common markers of bone loss. We evaluated BMD of the femoral neck using dual-energy X-ray absorptiometry, and the measured biochemical markers included serum bone-specific alkaline phosphatase (BALP), serum osteocalcin (OC), and serum cross-linked N-telopeptidases of type I collagen (NTx). Serum BALP and NTx concentrations were measured by enzyme-linked immunsorbent assay, and OC was measured using an immunoradiometric assay. One hundred and forty postmenopausal Japanese women who had not received treatment with bisphosphonates or hormone replacement therapy were entered into the study. Thirty-four patients (41.0%) had femoral osteopenia (T score ?1 to ?2.5) and 23 patients (27.7%) had osteoporosis (T < ?2.5). The body mass index of patients with normal BMD (T score ≥ ?1.0) was significantly higher (P < 0.01) than in patients with osteoporosis at the femoral neck. The T score exhibited a significant negative correlation with age and the duration of RA disease. Serum BALP and serum OC, markers of osteoblast function, were negatively related to erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3). However, serum NTx, a marker of resorptive function, exhibited a positive correlation with ESR, CRP, and MMP-3. From these results, this study suggests that generalized bone loss occurs in active RA and is characterized by evidence of bone resorption that is correlated with the high levels of inflammation. Body mass index, disease duration, and high serum NTx level were common risk factors in osteoporosis of postmenopausal women with RA.     

Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

The aim of the study was to compare the effects of once-weekly alendronate sodium and daily risedronate sodium treatment on bone mineral density (BMD) and bone turnover markers in postmenopausal osteoporotic subjects. For this purpose, 50 patients were included in this study and randomly classified into two groups. Group I (n=25) received risedronate (5 mg/day) and group II (n=25) received alendronate Na (70 mg/week). The study duration was limited to 12 months. The efficacy of the treatment was evaluated by BMD measurements at spine and hip at 6th and 12th months of the treatment, as well as by the measurement of bone turnover markers such as serum osteocalcin (OC), bone-specific alkaline phosphatase (BASP), urine deoxypyridinoline (DPD) and calcium/creatine ratio in 24-h urine at 1st, 3rd, 6th and 12th months. The evaluation of the changes in BMD in all regions revealed a significant increase in BMD in both groups compared to baseline values except for spine (L2–L4) in alendronate group at 6th and 12th month and femoral neck in risedronate group at 6th month. However, the difference in percentage increase in BMD measurements was not statistically significant between the two groups at 6th and 12th months. In both groups, serum OC, BSAP and urine DPD were found to be significantly attenuated at 1st month of the treatment period, and continued to be lowered throughout the 3rd, 6th and 12th months (P<0.05). However, there was no statistically-significant difference between both groups of patients (P>0.05). In conclusion, our results suggest that both treatment protocols provide treatment options of similar efficiencyfor postmenopausal osteoporosis, and have almost-similar effects in enhancing the BMD and in slowing the bone turnover. Risedronate seems to havea more potent effect in the spinal region than that of alendronate, although this potency was not statistically significant.     

The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis

The aim of this study was to investigate determinants of reduced bone mineral density (BMD) in postmenopausal women with active rheumatoid arthritis (RA) and to evaluate whether there are common markers of bone loss. We evaluated BMD of the femoral neck using dual-energy X-ray absorptiometry, and the measured biochemical markers included serum bone-specific alkaline phosphatase (BALP), serum osteocalcin (OC), and serum cross-linked N-telopeptidases of type I collagen (NTx). Serum BALP and NTx concentrations were measured by enzyme-linked immunsorbent assay, and OC was measured using an immunoradiometric assay. One hundred and forty postmenopausal Japanese women who had not received treatment with bisphosphonates or hormone replacement therapy were entered into the study. Thirty-four patients (41.0%) had femoral osteopenia (T score −1 to −2.5) and 23 patients (27.7%) had osteoporosis (T < −2.5). The body mass index of patients with normal BMD (T score ≥ −1.0) was significantly higher (P < 0.01) than in patients with osteoporosis at the femoral neck. The T score exhibited a significant negative correlation with age and the duration of RA disease. Serum BALP and serum OC, markers of osteoblast function, were negatively related to erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3). However, serum NTx, a marker of resorptive function, exhibited a positive correlation with ESR, CRP, and MMP-3. From these results, this study suggests that generalized bone loss occurs in active RA and is characterized by evidence of bone resorption that is correlated with the high levels of inflammation. Body mass index, disease duration, and high serum NTx level were common risk factors in osteoporosis of postmenopausal women with RA.     

绝经后妇女MMP-2和TIMP-2水平及其与骨密度和骨代谢指标的关系

目的 探讨绝经后妇女血清基质金属蛋白酶2（MMP-2）和组织金属蛋白酶抑制因子2（TIMP-2）水平及其与骨密度和骨代谢指标的关系。方法 对192名48～65岁绝经后妇女用酶联免疫吸附法（ELISA）测定的血清MMP-2、TIMP-2以及骨碱性磷酸酶（BAP）、骨钙素、Ⅰ型胶原交联C端肽（CTX），尿Ⅰ型胶原交联N端肽（NTX），计算MMP-2／TIMP-2比值，用双能X线吸收法（DEXA）测定腰椎正位，股骨颈，Ward三角和大粗隆的骨密度，按WHO标准将绝经后妇女分为骨密度正常、低骨量和骨质疏松3组。结果 （1）绝经后妇女骨质疏松患者血清MMP-2的水平（1388±121）μg／L高于骨密度正常组（1126±141）μg／L（P〈0．05），而TIMP-2的水平（44．3±38．2）μg／L稍低于骨密度正常组（47、3±30．2）μg／L（P〉0．05）。（2）血清MMP-2和MMP-2／TIMP-2比值与腰椎正位和Ward三角骨密度、血清BAP和骨钙素呈负相关（均P〈0．05），和尿NTx／Cr呈正相关（P〈0．05），MMP-2／TIMP-2比值还与股骨颈骨密度呈负相关（P〈0．05）。TIMP-2与腰椎正位和Ward三角骨密度、血清BAP和骨钙素呈正相关（均P〈0．05），和尿NTX／Cr呈负相关（P〈0．05）。在校正年龄和体重指数后，TIMP-2与腰椎正位骨密度和骨钙素无相关性（P〉0．05）。（3）骨质疏松组中血清MMP-2和MMP-2／TIMP-2比值与腰椎正位、股骨颈和Ward三角骨密度、血清BAP和骨钙素呈负相关（均P〈0．05），和尿NTX／Cr呈正相关（均P〈0．05），TIMP-2和Ward三角骨密度和BAP呈正相关（均P〈0．05）；在低骨量组中仅MMP-2与腰椎正位和Ward三角骨密度、骨钙素呈负相关（P〈0．05），和尿NTX／Cr呈正相关（P〈0．05），MMP-2／TIMP-2比值与Ward三角骨密度和血清BAP呈负相关（均P〈0．05）。结论 绝经后女性尤其是骨质疏松症妇女血清MMP-和MMP-2／TIMP-2比值与骨密度和骨代谢指标BAP、骨钙素和尿NTX／Cr具有关联性，血清MMP-2和MMP-2／TIMP-2比值增高可能为绝经后骨质疏松症伴随骨代谢转换过程增快的表现。     

老年男性各年龄组骨密度与骨代谢生化指标的关系

目的　测定老年男性不同年龄组骨密度及血、尿中与骨吸收和骨形成有关的生化指标 ,观察其与年龄的关系 ,探讨以上生化指标对早期诊断原发性骨质疏松的临床意义。方法　采用双能量 X线骨密度测定仪测定前臂骨密度 ;采用全自动生化分析法测定血清碱性磷酸酶(ALP)、尿钙 (Ca)、肌酐 (Cr) ;采用放免法测定骨钙素 (BGP)、抗酒石酸酸性磷酸酶 (TRAP)、尿羟脯氨酸 (HOP)。将年龄 60～ 95岁的老年男性 97例分为 60～ 69岁、 70～ 79岁和 80岁以上三组并与 60岁以下男性进行比较。再将其分为骨质疏松组与非骨质疏松组 ,比较其测定值。结果　老年男性骨密度及骨形成与骨吸收指标呈现随着年龄增长而降低的趋势。其中 ,骨质疏松组较非骨质疏松组骨钙素 (BGP)、抗酒石酸酸性磷酸酶 (TRAP)、尿羟脯氨酸 (HOP) ,明显下降 (P<0 . 0 5)。结论　老年男性骨质疏松属于低转换型 ,骨转换指标随增龄而呈下降趋势     

老年男性骨质疏松症患者骨密度和生化指标的变化

目的：了解老年男性骨质疏松症患者骨密度和骨代谢生化指标变化的特点。方法：对30例老年男性骨质疏松症患者进行腰椎（L2－4）骨密度（BMD）、骨矿含量（BMC）、血和尿骨代谢生化指标的测定,并与对照组进行比较。结果：骨质疏松（OP）组的BMD和BMC均显著小于对照组,分别比对照组下降21．6％和25％;OP组骨形成指标血清碱性磷酸酸（ALP）和C端骨钙素（BGP）明显高于对照组,分别上升25．4％和222％;骨吸收指标尿羟脯氨酸与肌酐的比值（HOP／Cr)和Ⅰ型胶原N－末端肽与肌酐的比值（INTX／Cr)明显高于对照组,分别上升22．6％和223％。OP组血清T水平明显低于对照组,两组血清25－羟维生素D3（25－OH－D3）均在正常低限或低于正常水平。结论：腰椎（L2－4）BMD和BMC是诊断男性骨质疏松症的主要依据;老年男性骨质疏松症患者一部分人属于骨代谢高转换型;雄激素对老年男性骨量的维持起重要作用;老年男性维生素D缺乏质疏松症发生的重要基础。